China High Quality Aminoacetaldehyde Dimethyl Acetal Factories – 99% Apixaban CAS 503612-47-3 – Baoran

Short Description:

Product Detail

Product Tags

Feedback (2)

We always think and practice corresponding to the change of circumstance, and grow up. We purpose at the achievement of a richer mind and body as well as the living for 1,3,5-Trimethylbenzene, 108-32-7, Cerium Nitrate, We guaranteed high quality, if clients were not satisfied with the products' quality, you can return inside 7days with their original states.

China High Quality Aminoacetaldehyde Dimethyl Acetal Factories – 99% Apixaban CAS 503612-47-3 – Baoran Detail:

Specification

ITEM	STANDARD
Appearance	White to off-white solid
Purity	≥ 99%

Application

On April 26, 2007, Bristol-Myers Squibb and Pfizer announced a joint development of the new oral anticoagulant apixaban owned by Bristol-Myers Squibb as an upgraded alternative to warfarin.
In May 2011, apixaban was the first to be approved for the prevention of venous thrombosis in adult patients undergoing elective hip or knee replacement surgery in 27 EU countries, Iceland and Norway.
On November 20, 2012, the European Commission approved ELIQUIS (apixaban) for the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF) with one or more risk factors.
The Canadian Food and Drug Administration, Japan, and the U.S. Food and Drug Administration subsequently approved ELIQUIS (apixaban) for the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF) with one or more risk factors.
On April 12, 2013, ELIQUIS (Apixaban), was officially announced on the market in China. Apixaban is a novel oral factor Xa inhibitor for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery. Its launch provides a safe and effective new option for anticoagulation after orthopaedic surgery in clinical practice, and brings good news to Chinese patients undergoing elective hip/knee replacement.
Clinical studies have confirmed that compared with 40 mg subcutaneous injection of enoxaparin once a day, 2.5 mg of ELIQUIS (Apixaban) orally twice a day is more effective in preventing venous thromboembolic events after hip or knee replacement surgery , and does not increase the risk of bleeding.

Packing & Storage

100g/500g/1kg/25kg or as request;
Stored at room temperature and airtight.

Product detail pictures:

Related Product Guide:

We retain bettering and perfecting our merchandise and service. At the same time, we do the job actively to do research and improvement for China High Quality Aminoacetaldehyde Dimethyl Acetal Factories – 99% Apixaban CAS 503612-47-3 – Baoran, The product will supply to all over the world, such as: Denmark, New Zealand, South Africa, Excellent quality comes from our adherence to every detail, and customer satisfaction comes from our sincere dedication. Relying on advanced technology and industry reputation of good cooperation, we try our best to provide more quality products and services to our customers, and all of us are willing to strengthen exchanges with domestic and foreign customers and sincere cooperation, to build a better future.

2-Nitro-1